Debiopharm is a privately-owned Swiss-based, biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases. As one of the few privately owned pharmaceutical companies engaged in the development of new antibiotics, we are developing highly targeted, pathogen-specific antibiotics effective against key bacteria, while sparing the microbiome. We’re seeking to address unmet medical needs in hard-to-treat infections through our novel class FabI inhibitors, including microbiome-sparing antibiotics such as afabicin for staphylococcal infections and Debio 1453 for gonorrhoeal infections.